Sonia Mahajan1, Joseph O'Donoghue2, Wolfgang Weber3, Lisa Bodei1. 1. Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, USA. 2. Department of Medical Physics and Radiology, Memorial Sloan Kettering Cancer Center, New York, USA. 3. Technical University of Munich, Germany.
Abstract
OBJECTIVE: To understand value of early rapid, quality-assurance (QA), post-therapy whole-body scan (Tx-WBS) in patients receiving peptide receptor radionuclide therapy (PRRT) in outpatient setting. METHODS: Sixteen patients with metastatic neuroendocrine tumors received PRRT and underwent Tx-WBS after each cycle. Early imaging (3 hour post-injection) was favored. Planar-images obtained on dual-headed gamma camera (speed 30 cm/min) were visually assessed and qualitatively compared with pre-therapy diagnostic scans. Retention% and lesion/spleen (L/S) ratios were calculated. RESULTS: Fifty three Tx-WBS were analyzed. No cutaneous contamination, extravasation or unexpected tracer distribution was observed. 46/53 (87%) Tx-WBS in 14/16 (88%) patients demonstrated uptake in metastatic lesions. No significant correlation was seen between L/S ratios and response on follow-up imaging. Qualitative assessment of follow-up images during four-cycles of PRRT provided preliminary estimate of disease course in 11/16 patients; with unexpected findings in 2. CONCLUSION: In daily practice, especially in outpatient setting, an early QA post-PRRT scan proved effective for validating successful treatment and allowing preliminary disease monitoring, at no additional cost.
OBJECTIVE: To understand value of early rapid, quality-assurance (QA), post-therapy whole-body scan (Tx-WBS) in patients receiving peptide receptor radionuclide therapy (PRRT) in outpatient setting. METHODS: Sixteen patients with metastatic neuroendocrine tumors received PRRT and underwent Tx-WBS after each cycle. Early imaging (3 hour post-injection) was favored. Planar-images obtained on dual-headed gamma camera (speed 30 cm/min) were visually assessed and qualitatively compared with pre-therapy diagnostic scans. Retention% and lesion/spleen (L/S) ratios were calculated. RESULTS: Fifty three Tx-WBS were analyzed. No cutaneous contamination, extravasation or unexpected tracer distribution was observed. 46/53 (87%) Tx-WBS in 14/16 (88%) patients demonstrated uptake in metastatic lesions. No significant correlation was seen between L/S ratios and response on follow-up imaging. Qualitative assessment of follow-up images during four-cycles of PRRT provided preliminary estimate of disease course in 11/16 patients; with unexpected findings in 2. CONCLUSION: In daily practice, especially in outpatient setting, an early QA post-PRRT scan proved effective for validating successful treatment and allowing preliminary disease monitoring, at no additional cost.
Authors: Saima Khan; Eric P Krenning; Martijn van Essen; Boen L Kam; Jaap J Teunissen; Dik J Kwekkeboom Journal: J Nucl Med Date: 2011-07-27 Impact factor: 10.057
Authors: Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245
Authors: Lisa Bodei; Marta Cremonesi; Chiara M Grana; Nicola Fazio; Simona Iodice; Silvia M Baio; Mirco Bartolomei; Dario Lombardo; Mahila E Ferrari; Maddalena Sansovini; Marco Chinol; Giovanni Paganelli Journal: Eur J Nucl Med Mol Imaging Date: 2011-09-03 Impact factor: 9.236
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Irvin M Modlin; Kjell Oberg; Daniel C Chung; Robert T Jensen; Wouter W de Herder; Rajesh V Thakker; Martyn Caplin; Gianfranco Delle Fave; Greg A Kaltsas; Eric P Krenning; Steven F Moss; Ola Nilsson; Guido Rindi; Ramon Salazar; Philippe Ruszniewski; Anders Sundin Journal: Lancet Oncol Date: 2008-01 Impact factor: 41.316
Authors: Ka Kit Wong; Kirk A Frey; Jeremy Niedbala; Ravi K Kaza; Francis P Worden; Kellen J Fitzpatrick; Yuni K Dewaraja Journal: Nucl Med Commun Date: 2022-06-10 Impact factor: 1.698
Authors: Else A Aalbersberg; Daphne M V de Vries-Huizing; Margot E T Tesselaar; Marcel P M Stokkel; Michelle W J Versleijen Journal: Cancer Imaging Date: 2022-06-17 Impact factor: 5.605